Clinical Trial of the Week: Study to determine if aspirin prevents breast cancer recurrence

By Donna Loyle, communications specialist, LIMR

Can treatment with simple aspirin prevent breast cancer recurrence in patients with node-positive, HER2-negative, stage 2 or 3 breast cancer after chemotherapy, surgery and/or radiation therapy? That’s the question this trial seeks to answer.

Participants receive either aspirin or a placebo orally once daily for five years, as long as the disease does not progress and there is no toxicity.

Inclusion criteria:

  • Must have been diagnosed within the past year and completed chemotherapy, surgery and/or radiation therapy, if applicable.
  • Any ER/PgR status is permitted.
  • Must be able to use acetaminophen, rather than aspirin, for minor pain relief and fever during the trial.
  • Must not be allergic to aspirin.
  • Other inclusion criteria apply; see website for details.

Study #A011502 is approved for all Main Line Health acute care hospitals. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email cancertrials@mlhs.org or visit https://bit.ly/2qq2efw.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *